Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Procalcitonin in Takayasu Arteritis

ENRICO TOMBETTI, MARIA CHIARA DI CHIO, SILVIA SARTORELLI, ANDREA SEGALINI, YOLE VELLA, MATTEO SPALLUTO, MARIA GRAZIA SABBADINI, ELENA BALDISSERA and ANGELO MANFREDI
The Journal of Rheumatology July 2014, 41 (7) 1564-1566; DOI: https://doi.org/10.3899/jrheum.131340
ENRICO TOMBETTI
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tombetti.enrico@hsr.it
MARIA CHIARA DI CHIO
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SILVIA SARTORELLI
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREA SEGALINI
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOLE VELLA
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MATTEO SPALLUTO
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA GRAZIA SABBADINI
Professor, Internal Medicine and Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELENA BALDISSERA
Assistant Professor of Rheumatology and Clinical Immunology, Unit of Internal Medicine and Immunology, San Raffaele Scientific Institute, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELO MANFREDI
Assistant Professor of Rheumatology and Clinical Immunology, Unit of Internal Medicine and Immunology, San Raffaele Scientific Institute, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Procalcitonin (PCT) is an acute-phase protein, a precursor of the hormone calcitonin1. Microbial constituents and proinflammatory mediators such as tumor necrosis factor-α (TNF), interleukin 6 (IL-6), and interferon-γ induce ubiquitous PCT expression during bacterial, parasitic, or fungal infections1,2. PCT enhances inflammatory response during sepsis, when excessive PCT production can be toxic, increasing mortality in animal models1. In humans, PCT has been demonstrated to be a more accurate marker of systemic bacterial infections than C-reactive protein (CRP)3, and it correlates with the severity of sepsis and mortality risk1. For these reasons, PCT is increasingly used for diagnosis, prognostic stratification, and treatment of patients with systemic bacterial or fungal infections. However, PCT elevation has been reported in noninfectious conditions, including inflammatory states associated with antineutrophil cytoplasmic antibodies-associated vasculitis, Kawasaki disease, and Goodpasture syndrome2. The clinical usefulness of PCT as a biomarker in patients with systemic autoimmune diseases has not been fully defined2. One metaanalysis showed that PCT had higher specificity but lower sensitivity than CRP in discriminating sepsis from disease flares4.

Takayasu arteritis (TA) is a rare, idiopathic inflammatory arteritis. TNF and IL-6, the cytokines responsible for systemic inflammatory reactions, have been proposed to be involved in TA pathogenesis and to represent possible therapeutic targets for TA5. Concordantly, systemic response with acute reactant elevation often but not always accompanies active disease5. To our knowledge, no data are available to assess the performance of PCT in TA. We thus wondered whether active TA was associated with PCT elevation in the absence of demonstrable systemic infection, possibly jeopardizing the differentiation between disease flares and bacterial sepsis.

Between March and June 2013, we evaluated levels of PCT, CRP, and erythrocyte sedimentation rate (ESR) in 41 consecutive patients with TA regularly followed at our center who had no concurrent systemic infections, as assessed by a thorough clinical assessment and parallel evaluation of leukocyte counts. Patient conditions were routinely verified again after 2 months, and in no case did infectious events become manifest in the 8 weeks after venipuncture. All patients with TA satisfied the American College of Rheumatology criteria for TA classification in the absence of a demonstrable infection. Activity status of TA was evaluated according to US National Institutes of Health criteria. In parallel, PCT and CRP were evaluated in a control group of 49 patients with severe sepsis and septic shock within 24 h from emergency room admission. All patients gave written consent to the study. PCT serum levels were assessed with electrochemiluminiscent immunoassay (ECLIA, Roche Diagnostics GmbH). Statistical elaborations were performed with SPSS statistic 15.0. Inferential statistic was performed with nonparametric tests.

Table 1 describes the principal characteristics of the 2 groups. The age at disease onset and sex distribution of the TA group was similar to other reports in the Italian population6. Mean prednisone dose was 6.4 mg/day (SD 8.1 mg/day). Twenty-nine patients took immunosuppressive agents, 16 received TNF inhibitors, and 2 tocilizumab. None of the patients with TA had increased PCT levels, although 14/41 patients (34%) had active TA and 14 and 13 patients, respectively, had increased ESR and CRP. Mean PCT value was 0.02 μg/l (SD 0.01 μg/l) and the maximum value was 0.08 μg/l (observed in a newly diagnosed untreated patient). TA activity influenced ESR and CRP but not PCT values, while concurrent immunosuppressive therapies did not influence any of the 3 biomarkers (Table 2). As expected, PCT levels were increased in the group of patients with severe sepsis and septic shock, where mean PCT was 28.8 μg/l (SD 53.3 μg/l). Our data thus indicate that PCT is not elevated in real-life clinical practice with patients with TA, not even during disease flares, suggesting that PCT could be used as a marker of sepsis in these subjects.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of the patients with TA (n = 41) and those with severe sepsis or septic shock.

View this table:
  • View inline
  • View popup
Table 2.

ESR, CRP, and PCT values in patients with TA according to activity status and concurrent immunological therapies.

Our study has limitations. First, it is a real-life cross-sectional analysis in which all patients with TA had already been diagnosed and followed. Thus, few patients had the very high inflammatory state that is sometimes present at disease onset before treatment. Second, because we do not have a control group of patients with septic TA, we cannot assess the sensitivity of PCT in this situation. A metaanalysis showed a relatively low sensitivity of PCT for diagnosing systemic infection in patients with autoimmune disease4, and it cannot be excluded that the immunodeficiency status associated with systemic autoimmune diseases and their treatments could limit PCT diagnostic accuracy. Patients with refractory TA are increasingly treated with biologic agents such as TNF or IL-6 inhibitors, and TNF has been proposed to induce in vivo the PCT synthesis1, although some findings do not confirm this hypothesis7. Given the importance of the diagnosis of systemic infections in immunocompromised patients, the assessment of PCT sensitivity in patients undergoing immunosuppressive regimens, especially those including agents blocking TNF and IL-6, needs further research.

Our results indicate that PCT is not elevated in patients with TA, and suggest that PCT elevations should raise the question of sepsis in these subjects.

Footnotes

  • Supported by the Ministero della Salute (Ricerca Finalizzata 2009 to Dr. Manfredi) and the Ministero dell’Istruzione, dell’Universitá e della Ricerca.

REFERENCES

  1. 1.↵
    1. Becker KL,
    2. Nylen ES,
    3. White JC,
    4. Muller B,
    5. Snider RH Jr.
    Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512–25.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Buhaescu I,
    2. Yood RA,
    3. Izzedine H
    . Serum procalcitonin in systemic autoimmune diseases—where are we now? Semin Arthritis Rheum 2010;40:176–83.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Simon L,
    2. Gauvin F,
    3. Amre DK,
    4. Saint-Louis P,
    5. Lacroix J
    . Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Wu JY,
    2. Lee SH,
    3. Shen CJ,
    4. Hsieh YC,
    5. Yo PH,
    6. Cheng HY,
    7. et al.
    Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012;64:3034–42.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tombetti E,
    2. Manfredi A,
    3. Sabbadini MG,
    4. Baldissera E
    . Management options for Takayasu arteritis. Expert Opin Orphan Drugs 2013;1:685–93.
    OpenUrlCrossRef
  6. 6.↵
    1. Vanoli M,
    2. Daina E,
    3. Salvarani C,
    4. Sabbadini MG,
    5. Rossi C,
    6. Bacchiani G,
    7. et al.
    Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 2005;53:100–7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Redl H,
    2. Schiesser A,
    3. Togel E,
    4. Assicot M,
    5. Bohuon C
    . Possible role of TNF on procalcitonin release in a baboon model of sepsis. Shock 2001;16:25–7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 7
1 Jul 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Procalcitonin in Takayasu Arteritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Procalcitonin in Takayasu Arteritis
ENRICO TOMBETTI, MARIA CHIARA DI CHIO, SILVIA SARTORELLI, ANDREA SEGALINI, YOLE VELLA, MATTEO SPALLUTO, MARIA GRAZIA SABBADINI, ELENA BALDISSERA, ANGELO MANFREDI
The Journal of Rheumatology Jul 2014, 41 (7) 1564-1566; DOI: 10.3899/jrheum.131340

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Procalcitonin in Takayasu Arteritis
ENRICO TOMBETTI, MARIA CHIARA DI CHIO, SILVIA SARTORELLI, ANDREA SEGALINI, YOLE VELLA, MATTEO SPALLUTO, MARIA GRAZIA SABBADINI, ELENA BALDISSERA, ANGELO MANFREDI
The Journal of Rheumatology Jul 2014, 41 (7) 1564-1566; DOI: 10.3899/jrheum.131340
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire